Cor­rect­ed: Sang­amo to seek ac­cel­er­at­ed ap­proval for Fab­ry gene ther­a­py, claims it won't need con­fir­ma­to­ry study

Sang­amo Ther­a­peu­tics thinks it’s found a faster, ear­li­er path­way to ap­proval for its Fab­ry dis­ease gene ther­a­py.

The biotech an­nounced Tues­day that it plans to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER